Clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 infection in a Latin American country: Results from the ECCOVID multicenter prospective study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
04
2021
accepted:
22
09
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Clinical features and outcomes of SARS-CoV-2 infections diverge in different countries. The aim of this study was to describe clinical characteristics and outcomes in a cohort of patients hospitalized with SARS-CoV-2 in Argentina. Multicenter prospective cohort study of ≥18 years-old patients with confirmed SARS-CoV-2 infection consecutively admitted to 19 hospitals in Argentina. Multivariable logistic regression models were used to identify variables associated with 30-day mortality and admission to intensive care unit (ICU). A total of 809 patients were analyzed. Median age was 53 years, 56% were males and 71% had at least one comorbidity. The most common comorbidities were hypertension (32%), obesity (23%) and diabetes (17%). Disease severity at admission was classified as mild 25%, moderate 51%, severe 17%, and critical 7%. Almost half of patients (49%) required supplemental oxygen, 18% ICU, and 12% invasive ventilation. Overall, 30-day mortality was 11%. Factors independently associated with ICU admission were male gender (OR 1.81; 95%CI 1.16-2.81), hypertension (OR 3.21; 95%CI 2.08-4.95), obesity (OR 2.38; 95%CI 1.51-3.7), oxygen saturation ≤93% (OR 6.45; 95%CI 4.20-9.92) and lymphopenia (OR 3.21; 95%CI 2.08-4.95). Factors independently associated with 30-day mortality included age ≥60 years-old (OR 2.68; 95% CI 1.63-4.43), oxygen saturation ≤93% (OR 3.19; 95%CI 1.97-5.16) and lymphopenia (OR 2.65; 95%CI 1.64-4.27). This cohort validates crucial clinical data on patients hospitalized with SARS-CoV-2 in Argentina.
Sections du résumé
BACKGROUND
Clinical features and outcomes of SARS-CoV-2 infections diverge in different countries. The aim of this study was to describe clinical characteristics and outcomes in a cohort of patients hospitalized with SARS-CoV-2 in Argentina.
METHODS
Multicenter prospective cohort study of ≥18 years-old patients with confirmed SARS-CoV-2 infection consecutively admitted to 19 hospitals in Argentina. Multivariable logistic regression models were used to identify variables associated with 30-day mortality and admission to intensive care unit (ICU).
RESULTS
A total of 809 patients were analyzed. Median age was 53 years, 56% were males and 71% had at least one comorbidity. The most common comorbidities were hypertension (32%), obesity (23%) and diabetes (17%). Disease severity at admission was classified as mild 25%, moderate 51%, severe 17%, and critical 7%. Almost half of patients (49%) required supplemental oxygen, 18% ICU, and 12% invasive ventilation. Overall, 30-day mortality was 11%. Factors independently associated with ICU admission were male gender (OR 1.81; 95%CI 1.16-2.81), hypertension (OR 3.21; 95%CI 2.08-4.95), obesity (OR 2.38; 95%CI 1.51-3.7), oxygen saturation ≤93% (OR 6.45; 95%CI 4.20-9.92) and lymphopenia (OR 3.21; 95%CI 2.08-4.95). Factors independently associated with 30-day mortality included age ≥60 years-old (OR 2.68; 95% CI 1.63-4.43), oxygen saturation ≤93% (OR 3.19; 95%CI 1.97-5.16) and lymphopenia (OR 2.65; 95%CI 1.64-4.27).
CONCLUSIONS
This cohort validates crucial clinical data on patients hospitalized with SARS-CoV-2 in Argentina.
Identifiants
pubmed: 34624038
doi: 10.1371/journal.pone.0258260
pii: PONE-D-21-11357
pmc: PMC8500444
doi:
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0258260Déclaration de conflit d'intérêts
Ezequiel Cordova is a consultant for Sinocell tech, Oncotelic and Janssen, is a speaker for Janssen, and received research grants from ViiV. Martin E. Stryjewski is a consultant for Basilea and Fulcrum, is a speaker for Pfizer, received research grants from NIH ARLG (UM1A104681), and is a sub-investigator in INSIGHT 0013 trial (NIH). Omar Sued is a consultant for ViiV, Eurofarma and Abbvie, and received research grants from NIH, Richmond Laboratory and ViiV. None of these conflicts are relevant to this article. All other authors report no conflicts of interest relevant to this article. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
PLoS One. 2021 Feb 11;16(2):e0246793
pubmed: 33571300
Sci Rep. 2020 Nov 3;10(1):18909
pubmed: 33144595
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Open Forum Infect Dis. 2020 Apr 29;7(5):ofaa153
pubmed: 32455147
Sci Rep. 2020 Dec 28;10(1):22402
pubmed: 33372194
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Clin Infect Dis. 2021 May 18;72(10):e558-e565
pubmed: 32856034
Radiology. 2021 Jun;299(3):E262-E279
pubmed: 33560192
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Int J Infect Dis. 2021 Jun;107:300-310
pubmed: 33444752
Mayo Clin Proc. 2020 Jun;95(6):1124-1126
pubmed: 32451119
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
BMJ Glob Health. 2020 Jul;5(7):
pubmed: 32718950
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Ann Intensive Care. 2011 Aug 01;1(1):29
pubmed: 21906383
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66
pubmed: 33119402
Rev Clin Esp. 2020 Nov;220(8):480-494
pubmed: 33994573
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
BMJ Open. 2020 Nov 6;10(11):e042946
pubmed: 33158840
BMC Infect Dis. 2021 Feb 8;21(1):157
pubmed: 33557778
JAMA Intern Med. 2021 Apr 1;181(4):471-478
pubmed: 33351068
J Clin Med. 2020 Jun 04;9(6):
pubmed: 32512688